<DOC>
	<DOCNO>NCT00328380</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability rifaximin 600 mg ( 3 x 200-mg tablet ) daily compare placebo take 14 day healthy subject prevent traveler ' diarrhea ( TD ) cause .</brief_summary>
	<brief_title>Prevention Travelers ' Diarrhea Subjects Traveling Outside U.S .</brief_title>
	<detailed_description>Travelers ' diarrhea ( TD ) common illness traveler develop world , occur 60 % international traveler high-risk area . It quite debilitate usual 2 4 day illness may lead disruption travel plan . Findings recent study indicate chronic post-travel illness may prove great clinical public health significance acute illness . Specifically , persistent diarrhea report 2 % 10 % traveler develop diarrhea . Moreover , bacterial enterocolitis , include associate TD , lead post-infectious irritable bowel syndrome 4 % 31 % patient .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>1 . Subject good health ( determined medical history ) 2 . Subject plan travel anywhere outside US ( except Canada ) least 5 14 day 3 . Subject schedule depart plan trip later 14 day earlier 4 day blood drawn clinical laboratory assessment urine collected pregnancy test ( female childbearing potential ) 1 . Subject hypersensitivity allergy rifaximin rifampin 2 . Subject know suspected alcohol abuse illicit drug use within 1 year enrollment 3 . Subject participate investigational drug device study within 30 day prior enrollment 4 . Subject receive rifaximin previous clinical study 5 . Subject receive systemic gastrointestinalspecific antibiotic within 7 day first dose study drug 6 . Subject receive antidiarrheal medication ( eg , loperamide , lactobacillus , BSS , KaopectateÂ® ) within 24 hour first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Travelers ' Diarrhea</keyword>
	<keyword>Xifaxan</keyword>
	<keyword>Rifaximin</keyword>
	<keyword>Escherichia coli</keyword>
	<keyword>E coli</keyword>
	<keyword>EAEC</keyword>
	<keyword>Enteroaggregative E coli</keyword>
	<keyword>ETEC</keyword>
	<keyword>Enterotoxigenic E coli</keyword>
</DOC>